Compare Neurocrine Biosciences Inc (NBIX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Union Pacific Corporation — how do they compare? Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B), while Union Pacific Corporation trades at $286.67 (market cap $169.16B). The key difference: Union Pacific Corporation is far larger — about 10.7× Neurocrine Biosciences Inc's market cap, and Union Pacific Corporation pays a 1.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | UNP | |
|---|---|---|
Market Cap | $15.77B | $169.16B |
Sector | Health | Industrials |
52-Week High | $185.50 | $310.62 |
52-Week Low | $123.10 | $214.91 |
Enterprise Value | $15.78B | $198.21B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Union Pacific (UNP) trades at $288.45, down 0.4% with a bearish technical signal despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($3.41 vs $3.26 expected) and maintains robust profitability with 28.85% net margin and 39.7% ROE. Recent news highlights progress on the Norfolk Southern merger, expected to close by late 2027, while institutional activity shows mixed positioning with some funds increasing stakes while others reduced exposure.
The stock offers upside to the $334.33 consensus price target with 58.7% analyst buy ratings, though technical resistance near $290-294 and merger regulatory risks warrant monitoring. Strong cash flow generation ($9.29B operating cash flow in 2025) and dividend payments ($1.42 declared for H2-26) support shareholder returns, while debt levels remain manageable at 46.06% debt-to-asset ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
